Novel Agent for Major Depression Moves to Phase III, Even With Setback

(MedPage Today) — Despite missing the primary endpoint, the novel KV7 potassium channel opener azetukalner showed benefit in major depressive disorder (MDD) in the phase II, proof-of-concept, randomized X-NOVA trial.
While the mean reduction…